Phuong T. Tran

Phuong T. Tran

Auto-generated profile, based on publicly available information

Phuong T. Tran

Department of Pharmaceutical Outcomes and Policy, College of Pharmacy University of Florida Gainesville Florida USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2018 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
PDF file
MMMichael Muriello
Michael Muriello
JCJulia L. Clemens
Julia L. Clemens
WMWeiyi Mu
Weiyi Mu
PTPhuong T. Tran
Phuong T. Tran
PRPeter Rowe
Peter Rowe
AKAntonie D. Kline
Antonie D. Kline
The objective of this study was to explore the factors contributing to quality of life in pediatric patients with non‐vascular Ehlers–Danlos syndromes (EDS). Data were analyzed on 41 children with a diagnosis of non‐vascular EDS from the de‐identified data available from the National Institute on Aging (NIA) study of heritable disorders of connective tissue. Children under age 19 years were seen as part of a long‐term evaluation project from 2003 to 2013 on a larger natural history of patients with heritable disorders of connective tissue. Data collected included medical history, physical examination findings, diagnostic study results, and responses on validated questionnaires. We reviewed a sub‐cohort of children with a diagnosis of non‐vascular EDS and explored pain severity and interference via the Brief Pain Inventory, and sleep quality via the Pittsburgh Sleep Quality Index. Pain severity had a strong correlation with pain interference, and both were similar to other disorders that include chronic pain reported in the literature. Sleep quality did not correlate with pain severity or interference, but all patients had poor sleep quality in comparison to historical controls. We conclude that pain and sleep are significant issues in the pediatric non‐vascular EDS population, and future research may be directed toward these issues.

1 August 2018 in Annals of Epidemiology
Verified
Journal Article
Closed access
PTPhuong T. Tran
Phuong T. Tran
AMAlan K. Meeker
Alan K. Meeker
EPElizabeth A. Platz
Elizabeth A. Platz

1 July 2024 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
PTPhuong T. Tran
Phuong T. Tran
SNSabina O. Nduaguba
Sabina O. Nduaguba
YWYanning Wang
Yanning Wang
VDVakaramoko Diaby
Vakaramoko Diaby
LFLynn Finelli
Lynn Finelli
AWAlmut G. Winterstein
Almut G. Winterstein
Background: The cost of medically attended RSV LRI (lower respiratory infection) is critical in determining the economic value of new RSV immunoprophylaxes. However, most studies have focused on intermittent RSV encounters, not the episode of care that captures the entirety of RSV illness.Methods: We created age‐ and condition‐specific cohorts of children under 5 years of age using MarketScan® data (2015–2019). We contrasted aggregating healthcare costs over RSV‐LRTI episodes to ascertaining costs based on RSV‐specific encounters only. Economic burden was estimated by multiplying costs per encounter or per episode by their respective incidence rates.Results: Average cost was higher per episode than per encounter regardless of settings (inpatient: $28,586 vs. $18,056 and outpatient/ED: $2099 vs. $407 for infants). Across ages, the economic burden was highest for infants and RSV‐LRTI requiring inpatient care, but the burden in outpatient/ED settings was disproportionately higher than costs due to higher incidence rates (for inpatient vs. outpatient episodes: $226,403 vs. $101,269; for inpatient vs. outpatient encounters: $151,878 vs. $38,819 per 1000 infant‐years). For high‐risk children, cost and burden were up to 3–10 times higher, respectively.Conclusions: With a comprehensive stratification by settings and risk condition, the encounter‐ versus episode‐based estimates provide a robust range for policymakers' economic appraisal of new RSV immunoprophylaxes.

30 April 2022 in Clinical Drug Investigation
Verified
Journal Article
Closed access
PDF file
PTPhuong T. Tran
Phuong T. Tran
MRMunaza Riaz
Munaza Riaz
ZCZiyan Chen
Ziyan Chen
CTCong Bang Truong
Cong Bang Truong
VDVakaramoko Diaby
Vakaramoko Diaby

3 April 2025 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
SNSabina O. Nduaguba
Sabina O. Nduaguba
PTPhuong T. Tran
Phuong T. Tran
RSRenata Shih
Renata Shih
LFLyn Finelli
Lyn Finelli
YCYoonyoung Choi
Yoonyoung Choi
AWAlmut G. Winterstein
Almut G. Winterstein
Objectives: This study aimed to estimate the incidence of respiratory syncytial virus (RSV) infections in US inpatient and outpatient settings.Methods: We established national cohorts of privately insured children < 5 years (2011–2019) to estimate annual and seasonal incidences of lower respiratory tract infection (LRTI), RSV‐LRTI, and RSV acute respiratory infection (RSV‐ARI), stratified by age and high‐risk conditions per American Academy of Pediatrics definitions. Sensitivity analyses varied episode definitions and assessed the impact of immunoprophylaxis and RSV under‐ascertainment.Results: Among 6,767,107 children, annual RSV‐LRTI rates dropped with increasing age in both inpatient (7.9 for age < 1 year to 0.2 for age 4 per 1000 person‐years) and outpatient settings (48.3 to 1.6). Most RSV‐ARI (~80%–90%) was RSV‐LRTI. RSV‐LRTI accounted for > half of LRTI hospitalizations among infants (7.9 RSV‐LRTI versus 14.7 LRTI) and for ~20% outpatient LRTI (48.3 versus 250.3), but this contribution declined with older age. Outpatient RSV‐LRTI was > 5 times inpatient rates.Inpatient RSV‐LRTI rates dropped consistently with increasing gestational age (GA) (35.6 for GA < 29 weeks versus 7.6 for term infants), while outpatient rates were similar across GA groups (54.0 versus 51.6). Infants with Down syndrome had the highest RSV‐LRTI rates, and any high‐risk group had rates >2 times higher than healthy term infants. Across all strata, seasonal rates were > 2 annual rates. Modeling suggested that claims data captured 42% of all RSV episodes.Conclusion: This study provides national, population‐based estimates of medically attended RSV infections across age groups and high‐risk strata. Results allow granular assessments of disease burden to guide recommendations for new RSV prevention strategies.

21 September 2022 in Journal of Child Health Care
Verified
Journal Article
Closed access
YWYou Wang
You Wang
JCJulia L Clemens
Julia L Clemens
MMMichael Muriello
Michael Muriello
WMWeiyi Mu
Weiyi Mu
CSChristy H Smith
Christy H Smith
JBJoann Bodurtha
Joann Bodurtha
Hypermobile Ehlers-Danlos syndrome (hEDS) is a common disorder in children and adolescents that negatively impacts health-related quality of life (HRQOL). It can include chronic pain, fatigue, autonomic dysfunction, and mood problems. The objective of this study was to examine levels of agreement between children and parents in the setting of hEDS and HRQOL. Individuals with hEDS, ages 10-20 years, and their parents were recruited to complete a series of surveys. Instruments included pediatric quality of life generic and multidimensional fatigue scales, Functional Disability Index, Pain-Frequency-Severity-Duration scale, Brief Illness Perception Questionnaire, and Herth Hope Index. Agreement on each measure was evaluated using statistical calculations. Thirty-six parent-child dyads completed the surveys. There were no significant differences between the means of parent and child scores. There was moderate to strong agreement on all survey scores. However, the proportion of dyads with disagreement was relatively high for each individual score. Eighteen dyads disagreed on at least half of the surveys. Body mass index centile and child perception of cognitive fatigue most strongly predicted disagreement in total HRQOL score. Proxy-reporters for children and adolescents with hEDS may agree with their child on average. However, due to significant frequency of clinically important disagreement, information from both children and their parents should be sought whenever possible.